MedWatch

Bank skeptical about Novo Nordisk share price – requires USD 40bn a year in obesity drug sales

Berenberg is baffled by Novo Nordisk's share price, which according to the Germany-based bank, would require an almost impossible sales volume for obesity drug Wegovy.

Photo: Novo Nordisk/PR

A new analysis conducted by German bank Berenberg has left it with questions about Novo Nordisk's share price, which currently reflects a market expectation that its obesity drug Wegovy will acheive peak sales of USD 40bn (DKK 250bn) a year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs